KLRC1 and non-small cell lung carcinoma: The most promising anti-NKG2A mAb, called monalizumab, prevents the interaction between NKG2A and HLA-E and exhibits a potent therapeutic impact on several cancer types, such as NSCLC, CRC, and SCCHN [106].